title: Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies.
abstract: Different Leishmania species rely to different extents on abundant glycoconjugates, such as lipophosphoglycan (LPG) and related molecules, in mammalian infections. Previously, we showed that Leishmania major deletion mutants lacking the Golgi GDP-mannose transporter LPG2, which is required for assembly of the dominant phosphoglycan (PG) repeats of LPG, were unable to survive in macrophages. These lpg2- mutants, however, retained the ability to generate asymptomatic, persistent infections in mice. In contrast, Ilg and colleagues showed that Leishmania mexicana LPG2 mutants retained virulence for mice. Here we identified a partial revertant population of the L. major lpg2- mutants (designated lpg2(-)REV) that had regained the ability to replicate in macrophages and induce disease pathology through a compensatory change. Like the lpg2 parent, the lpg2(-)REV revertant was unable to synthesize LPG2-dependent PGs in the promastigote stage and thus remained highly attenuated in the ability to induce infection. However, after considerable delay lpg2(-)REV revertant-infected mice exhibited lesions, and amastigotes isolated from these lesions were able to replicate within macrophages despite the fact that they were unable to synthesize PGs. Thus, in some respects, the lpg2(-)REV amastigotes resemble L. mexicana amastigotes. Future studies of the gene(s) responsible may shed light on the mechanisms employed by L. major to survive in the absence of LPG2-dependent glycoconjugates and may also improve the potential of the lpg2- L. major line to serve as a live parasite vaccine by overcoming its tendency to revert toward virulence.
authors.affiliation: Department of Molecular Microbiology, Washington University Medical School, St. Louis, Missouri 63110, USA.
authors.forename: Gerald F
authors.initials: GF
authors.lastname: Späth
authors.forename: Lon-Fye
authors.initials: LF
authors.lastname: Lye
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Segawa
authors.forename: Salvatore J
authors.initials: SJ
authors.lastname: Turco
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Beverley
mesh_terms: D000818:Animals; D005260:Female; D006001:Glycoconjugates / Q000378:metabolism; D006028:Glycosphingolipids / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007114:Immunization; D018320:Leishmania major / Q000235:genetics / Q000254:growth & development* / Q000276:immunology / Q000472:pathogenicity; D016773:Leishmaniasis, Cutaneous / Q000469:parasitology* / Q000503:physiopathology / Q000517:prevention & control; D017737:Macrophages, Peritoneal / Q000469:parasitology*; D008565:Membrane Proteins / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D015800:Protozoan Proteins / Q000235:genetics* / Q000378:metabolism; D016052:Protozoan Vaccines; D014774:Virulence
chemical_list: D006001:Glycoconjugates; D006028:Glycosphingolipids; C095909:LPG2 protein, Leishmania; D008565:Membrane Proteins; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; C008290:lipophosphonoglycan